Localization of FAM171B mRNA Expression In Mouse Brain Using In-Situ Hybridization by Sudasinghe, Ashani Kumudika
Minnesota State University, Mankato
Cornerstone: A Collection of
Scholarly and Creative Works for
Minnesota State University,
Mankato
All Theses, Dissertations, and Other Capstone
Projects Theses, Dissertations, and Other Capstone Projects
2017
Localization of FAM171B mRNA Expression In
Mouse Brain Using In-Situ Hybridization
Ashani Kumudika Sudasinghe
Minnesota State University, Mankato
Follow this and additional works at: http://cornerstone.lib.mnsu.edu/etds
Part of the Amino Acids, Peptides, and Proteins Commons, and the Neurosciences Commons
This Thesis is brought to you for free and open access by the Theses, Dissertations, and Other Capstone Projects at Cornerstone: A Collection of
Scholarly and Creative Works for Minnesota State University, Mankato. It has been accepted for inclusion in All Theses, Dissertations, and Other
Capstone Projects by an authorized administrator of Cornerstone: A Collection of Scholarly and Creative Works for Minnesota State University,
Mankato.
Recommended Citation
Sudasinghe, Ashani Kumudika, "Localization of FAM171B mRNA Expression In Mouse Brain Using In-Situ Hybridization" (2017).
All Theses, Dissertations, and Other Capstone Projects. 735.
http://cornerstone.lib.mnsu.edu/etds/735
 Localization of FAM171B mRNA Expression 
In Mouse Brain Using In-Situ Hybridization 
by 
Ashani Kumudika Sudasinghe 
 
 
 
 
A Thesis Submitted  
In Partial Fulfillment of the Requirements 
For the Degree of Master of Science in Biology 
In Biological Sciences 
 
 
 
 
 
 
 
 
 
Minnesota State University, Mankato, MN 
Department of Biology 
August 16th, 2017 
 
 
 
  
(08/16/2017) 
 
Localization of FAM171B in mRNA Expression in Mouse Brain Using In-Situ    
Hybridization 
 
Ashani Sudasinghe 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This thesis has been examined and approved by the following members of the student’s 
committee. 
 
 
 
Geoffrey Goellner, Ph.D. 
     Advisor 
 
 
 
David Sharlin, Ph.D. 
Committe member 
  
 
Rachel Cohen, Ph.D.  
Committee member 
 
 
 
 
 
 
 
  
Abstract 
Localization of FAM171B mRNA Expression 
In Mouse Brain Using In-Situ Hybridization 
Name - Ashani Sudasinghe 
Degree- Masters of Science in Biology 
University- Minnesota State University Mankato MN56001 
Year- 2017 
 
Proteins containing polyglutamine (polyQ) tracts within their primary amino acid 
sequence are particularly interesting because expansion mutation within them has been 
shown to underlie a growing list of severe neurodegenerative disorders including 
Huntington’s Disease and several types of Spinocerebellar Ataxias. FAM171B is a novel 
polyQ protein that was originally identified via large scale sequencing efforts. However, 
to date, very little is known regarding its normal cellular function and expression pattern. 
In this study, in situ hybridization was utilized to assess whether FAM171B is expressed 
in developing (postnatal days 7, 21, 42) and adult mouse brains. The results of the 
experiments performed suggest that FAM171B is indeed expressed in the brain, with 
pronounced expression in the hippocampus, Purkinje cells of the cerebellum, and cerebral 
cortex. Given these findings, FAM171B should be considered a candidate gene for 
exploration of molecularly uncharacterized neurodegenerative diseases. 
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Chapter 1 
Introduction 
While the human genome encodes approximately 20,000 proteins; a substantial 
number of them remain uncharacterized (1). One such novel gene product is the 92kD 
protein FAM171B (2).  Although there is minimal published data regarding the molecular 
function of FAM171B in cells, some important characteristics can be inferred from the bio-
informatic analysis of its amino acid sequence.  For example, FAM171B is predicted to 
contain an A-T hook within its structure. Since A-T hooks are DNA binding domains, 
FAM171B may therefore have a nuclear function. Additionally, FAM171B contains a 
polyglutamine (polyQ) region within its primary amino acid sequence (2).  PolyQ proteins 
are particularly interesting, as mutations in these regions have been shown to underlie a 
growing list of severe neurodegenerative disorders (3).  
Polyglutamine disorders are classified by nine neurodegenerative diseases (Table 
1). Severe neurodegenerative disorders such as Huntington’s Disease, several 
Spinocerebellar Ataxias (SCA 1,2,3,6,7,17), Spinal-Bulbar Muscular Atrophy (SBMA), 
and Dentatorubral-Pallidoluysian Atrophy (DRPLA) are all caused by mutations in polyQ 
stretches within their respective gene products (3, 4) (5).  All polyQ diseases are 
progressive and ultimately fatal disorders without a known cure (5). In each polyQ 
disorder, the glutamine sequence, which is coded for by cysteine, adenine and guanine as 
a trinucleotide (CAG) within the mRNA coding region, (8) extends well beyond its normal 
range leading to specific cell loss within the brain and consequent disease (5) (6). An 
interesting feature regarding this phenomenon is that the longer the polyQ stretch within 
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the protein, the more severe the disease manifests -- clearly implicating the polyQ region 
itself as being the toxic agent (5) (7).  The damage results from the toxic gain of function 
of protein aggregates due to expansion of translated CAG repeats (7) (9). 
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Table1. Polyglutamine disorders with normal and mutant CAG repeats & the brain regions 
that are affected (10-19). 
Spinocerebellar ataxia type 1 (SCA1) (Table 1) is an inherited polyglutamine 
neurodegenerative disorder characterized by ataxia, the loss of voluntary controlled 
Disease 
Type of 
nucleotide 
Normal 
Range 
Mutant 
range 
Most affected Brain 
region 
Huntington’s 
Disease 
CAG 11-34 37-121 Caudate, Cerebral Cortex 
Spinocerebellar 
Ataxia type 1 
(SCA1) 
CAG 19-36 42-81 
Cerebellar Purkinje cells 
brain stem 
Spinocerebellar 
Ataxia type 2 
(SCA2) 
CAG 15-29 35-59 
Cerebellar Purkinje cells 
brain stem 
Machado-Joseph 
Ataxia  (SCA3) 
CAG 12-40 66-200 
Cerebellar Dentate 
neurons, basal ganglia, 
brain stem 
Spinocerebellar 
Ataxia Type 6  
(SCA6) 
CAG 4-16 21-28 
Cerebellar purkinje cells, 
Dentate nucleus 
Spinocerebellar 
Ataxia Type 7 
(SCA7) 
CAG <64 >64 Brain stem. cerebellum 
Spinocerebellar 
Ataxia Type 12 
(SCA12) 
CAG 9-28 55-78 Cerebellum 
Spinocerebellar 
Ataxia Type 17 
(SCA17) 
CAG 29-42 47-55 Cerebellar Purkinje cells 
Dentatorubral-
Pallidoluysian 
Atropy (DRPLA) 
CAG 7-34 49-83 
Cerebellum, basal 
ganglia, Cerebral Cortex 
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coordination of muscle movements and progressive bulbar dysfunction (10). Unaffected 
individuals possess ~6-39 CAG repeats within the SCA1 gene located on the short arm of 
chromosome 6 (10). An affected individual, in contrast, can exhibit anywhere from 40 to 
81 CAG repeats within the SCA1 gene (10).  
Spinocerebellar ataxia type 2 (SCA2) (Table 1) is an autosomal dominantly 
inherited neurodegenerative disorder that results from an expansion of CAG repeats within 
the ATXN2 gene (11). SCA type 2 disorder, which causes damage primarily to cerebellar 
purkinje cells (11), produces several symptoms, with progressive ataxia dominating. 
Unaffected individuals can exhibit from 14 up to 31 CAG repeats while affected persons 
are known to possess more than 32 CAG residues within the ATXN2 gene (11). 
  Spinocerebellar Ataxia type 3 (Table 1), also known as Machado-Joseph disease, 
is the most commonly inherited Spinocerebellar ataxia. Persons diagnosed with this 
disorder exhibit 61-84 CAG repeats within their MJD1 gene, resulting in neuronal 
degeneration of the basal ganglia, brain stem, spinal cord and cerebellum (12). Unaffected 
individuals, on the other hand, contain a much lower number (12-37) CAG repeats within 
the MJD1 gene (12). 
 Spinocerebellar Ataxia type 6 (Table 1) primarily affects the cerebellum, in 
particular the purkinje cells (13). Unaffected individuals exhibit 4-20 CAG repeats within 
the SCA6 gene while the diseased gene can possess from 21 up to 33 CAG repeats (13).  
 Spinocerebellar Ataxia type 7 (Table 1) results in severe neuronal loss in the 
inferior olivary complex as well as damage to neuronal cells of the cerebral cortex (14).  
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CAG repeats within the pathological gene can vary between 37 and 200 CAG repeats 
whereas in the normal SCA7 gene, there are less than 36 CAG repeats (14).  
 Spinocerebellar ataxia type 12 (SCA12) is a slowly progressive neurodegenerative 
disorder that is dominantly inherited. Action tremors, anxiety and depression are the most 
common symptoms associated with this disorder (15).  SCA12 results from expansion of 
the CAG repeats within the PPP2R2B gene. Unaffected individuals contain 7-28 CAG 
repeats within this gene. Diseased individuals, on the other hand, can exhibit anywhere 
from 55-78 CAG repeats (15) (Table 1). 
 Spinocerebellar Ataxia type 17 (SCA17) is characterized by ataxia, dementia and 
involuntary muscle movements, resulting in chorea (uncontrollable motor dysfunction) and 
dystonia (involuntary muscle movements). Patients with this disorder start to express 
symptoms at mid age (16). Neuronal damage occurs mainly within the cerebellum, brain 
stem and cerebrum. The TBP gene, which is affected by the number of CAG repeats 
present, encodes a TATA box binding protein that is necessary for transcription to take 
place (16). Unaffected individuals contain 25-40 CAG repeats within the TBP gene 
whereas affected persons contain 41-48 CAG repeats within this gene (16) (Table 1).  
 Dentatorubral and pallidoluysian atrophy (DRPLA) is another polyglutamine 
neurodegenerative disorder that is characterized by ataxia and abnormal muscle control, 
but affected persons also experience tremors, seizures and even premature death. This 
disease is inherited in an autosomal dominant fashion and like SCA17 occurs in middle- 
aged individuals (17).  In these persons, neuronal damage and gliosis occur in many regions 
of the brain, although the Dentate nucleus of the cerebellum, the red nucleus, the Globus 
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pallidus and the sub-thalamic nucleus show prominent neuronal damage (17).  In 
unaffected individuals, the CAG repeat sequence within the atrophin-1 gene can vary 
between 6 to 35 CAG repeats (Table 1). Meanwhile, individuals with DRPLA can possess 
from 49 up to 88 CAG repeats within this gene (17). 
 Huntington’s disease is an autosomal dominantly inherited neurodegenerative 
disorder categorized by chorea, cognitive decline, dementia and ultimately death within 
15-20 years of being diagnosed (3). Interestingly, Huntington’s disease is characterized by 
putative and progressive clinically irreversible symptoms involved with neural protein 
aggregates (18) that are caused by polyglutamine expansion within the Huntingtin (HTT) 
gene on the short arm of chromosome 4. Unaffected individuals typically contain 26 or 
fewer polyglutamine repeats within the HTT gene while affected persons exhibit between 
40 and ~100 CAG repeat sequences (Table 1). In the later group, the disease usually 
manifests itself in mid-life but the symptoms may not appear until much later in life due to 
reduced penetrance of the CAG repeat regions. It is interesting to note that as the Huntingtin 
gene is passed on to the next generation from an affected parent (50% chance of 
transmitting the abnormal HTT gene to his/her children (19)), the polyglutamine regions 
can expand. The severity and manifestation of the disease, however, is directly dependent 
on the number of CAG repeats in the HTT gene: (1) 27-35 CAG repeats – these individuals 
do not exhibit Huntington’s disease but there is a high probability of them transmitting the 
disease to the next generation, (2) 36-39 CAG repeats – these persons may or may not be 
affected by Huntington’s disease due to reduced penetrance, and (3) ≥40 CAG repeats – 
these individuals will always exhibit Huntington’s disease (19) (Table 1).  
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According to Nelson et. al. (21), expansion of polyQ stretches somehow endows 
proteins with a toxic gain of function that ultimately kills neurons.  Even though each 
polyglutamine disease is rare, as a group these are the most common form of inherited 
neurodegenerative diseases (7).  
Mesenchymal stem cells, also known as marrow stromal cells (MSC), have been 
used as a therapeutic tool for cell therapy as well as in many clinical trials that have been 
approved by the FDA (22). Myocardial infarction, strokes and autoimmune disorders are a 
few of the many disorders that MSCs have been used as a tool for therapeutic advantage.  
Nowadays, researchers are showing a great interest in determining whether or not MSCs 
can be used to treat neurodegenerative disorders, especially diseases like Huntington’s 
disease that are progressive and fatal (22). Pre-clinical trials suggest that transplantation 
(via intracerebral or intrathecal injection) of mesenchymal stem cells into the brain endorse 
endogenous neuronal growth, decrease apoptosis, and increase paracrine secretions that 
can be used to regenerate synaptic connections of already damaged neurons and control 
inflammation (22). As such, mesenchymal stem cells can provide a potential regenerative 
approach for those progressive and fatal neurodegenerative disorders. Ongoing clinical 
trials where MSC’s were directly injected in to the central nervous system during traumatic 
brain injuries support the current hypothesis regarding the use of MSCs as a therapeutic 
tool for neuronal cell regeneration in the brain (22). 
Since FAM171B also includes a PolyQ stretch within its protein, it is interesting to 
further investigate about this uncharacterized protein. Although it is not clear whether the 
newly identified polyQ protein FAM171B will ever be linked to a particular disease, polyQ 
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proteins in general are fascinating because of their common role in neurodegenerative 
disease. Moreover, uncovering the normal cellular function of a novel human protein, in 
this case FAM171B, is a worthwhile endeavor that will advance the field of cellular 
biology.  Thus, the current project was undertaken to gain insight about the novel polyQ 
protein FAM171B, and specifically answer questions regarding which body tissues it is 
normally expressed in. If our findings show that FAM171B is expressed in the brain, then 
FAM171B could potentially be considered a candidate gene for exploring a molecularly 
uncharacterized neurodegenerative disease. 
The methodology that was employed to accomplish the abovementioned goal, is a 
method coined in-situ hybridization. This specialized staining technique relies on Watson 
and Crick base pairing between polynucleotides within its complementary RNA sequence 
(23). In-situ hybridization is a standard molecular technique that harnesses the power of 
nucleotide base pairing that occurs between complementary bases in RNA, to investigate 
for expression of specific genes in tissues of the body. Additionally, this technique can be 
highly sensitive when a targeted nucleic acid sequence is in a small percentage of cells or 
in specific regions of an organ (24). In-situ hybridization is commonly used in cell biology 
to localize mRNA via light microscopy (23). Hybridization products are obtained via a 
phosphatase coupled antibody reaction against the degoxygenin products (25).  Following 
sample fixation and embedding procedures, the sample can be analyzed using  
a light microscope to visualize gene expression (24). In-order-to observe and analyze the 
expression of FAM171B mRNA in brain tissue, brains from mice representing four 
different age groups were harvested. Mice brains were used in this study given that 
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genomic sequencing data suggests that mice contain a FAM171B protein that is ~ 88% 
identical in sequence to the human FAM171B protein although the number of 
polyglutamine repeats does vary (16 in humans versus whereas 7 in mice) (39). 
 
Hypothesis 
In the current study, it is hypothesized that FAM171B will be expressed in the 
brains of mice and that the expression may be temporally or spatially specific.  To test this 
hypothesis, in-situ hybridization will be performed on various regions of brain tissue 
harvested from laboratory mice representing four different age groups. 
 
Prediction 
 Observation of FAM171B is anticipated in the different regions of the mouse brain, 
although the expression of this protein may vary between the different regions of the brain. 
Expression of FAM171B is also expected to vary in a time-wise manner of the mouse life 
cycle, thus we will be able to detect this time-based expression by examining the brain 
tissue of mice belonging to different age groups. 
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Chapter 2 
Methods and Materials 
2.1 FAM171B Amplification  
PCR was conducted to amplify FAM171B cDNA from mouse cochlea to insert the 
gene product in to a pGEM-T Easy vector. 12.5μl of Promega gotaq master mix (2X), 1μl 
of appropriate primers (10mM) (Primer sequences shown in Figure 4, Appendix), 2μl of 
DNA template (Cochlea cDNA) and 8.5μl H2O were mixed. Reaction PCR cycle ran in 
95°C for 2 min, 95°C for 30sec, 55°C for 30 sec. Reaction was extended at 72°C for 1 min. 
This reaction was repeated for 30 cycles. Reaction was then kept in 72°C for 5 min and 
stored at 4°C.  
PCR products were analyzed by agarose gel electrophoresis (Figure 1, Results) and 
sent for sequence verification (Appendix, Figure 5 and 6). PCR clean-up was performed 
accordingly to manufacturer instructions (Quiagen). In short, pH should be less than 7.5 
for PCR purification. Buffer PB, DNA and pH indicator was added to the spin column. 
Supernatant was discarded after centrifuging at 16000xg for 1 min. Buffer PE (750μl) was 
added to the spin column and centrifuged for 1 min. The microcentrifuge tube was replaced 
after another 1min centrifuge and supernatant was discarded.  30μl of the eluting buffer 
was added to the spin column with DNA and incubate 1min. Flow through was collected 
after 1 min centrifugation. 
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2.2 Gel Confirmation of FAM171B Insert Generation  
1% Agarose gel was made using 0.6g of Agarose in 60ml of 1% TAE buffer and 
by adding 1.2μl Ethidium Bromide. 2μl of 6X-loading dye was added to the prepared 10μl 
DNA samples. 12μl of 1Kb bio-life DNA ladder (NEB) was inserted to the 1st well of the 
gel. Gel electrophoresis was conducted in 96V for 45 Min (Figure 1, Results). 
2.3 Sub-clone FAM171B into a pGEM-T Easy Vector 
TA cloning was performed using 7.5μl 2X rapid ligase buffer, 1 μg pGEM-T Easy 
vector, 0.5μl PCR product (DNA insert), 1.5μl T4 DNA ligase was mixed in micro 
centrifuge tubes and stored at 4°C overnight. (Appendix figure, 1) 
2.4 Transformation 
LB/Ampicillin/ IPTG/X-Gal plates were prepared. Ligation reaction mixture was 
centrifuged and 1.5μl of each ligation reaction was added to a sterile 1.5ml tube. JM109-
L2005 high efficiency competent cells were placed in an ice bath until just thawed (5min). 
Cells were mixed by gently flicking the tube and 25μl of cells were transferred to the 
ligation reaction tubes. Mixture was gently mixed and incubated on ice for 30mins. Cells 
were heat-shocked for 25 Sec in a water bath at 42°C. Tubes were then immediately 
returned to the ice for 2 min. 450μl of room temperature LB medium was added to the 
ligation reaction transformation and incubated for 60mins at 37°C.  100μl of each 
transformation culture was then added to LB/Ampicillin/IPTG/X-Gal plates. Plates were 
incubated overnight at 37°C, and only the white colonies were selected (Figure 2, 
Appendix). 
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5ml of LB broth and 5μl of ampicillin were mixed to make liquid bacterial cultures. 
One isolated white colony was inserted to the mixture and incubated at 37°C for 18 hrs. 
For glycerol stocks, 1ml of culture was added to the 1.5 ml storage tubes and bacteria were 
pelleted.  25% glycerol and fresh LB broth was added to the tube, and glycerol stocks were 
stored at -80°C. 
2.5 Isolating the vector with FAM171B gene 
A quiagen mini-prep was used to isolate pGEM T-easy vector containing 
FAM171B according to manufacturer instructions.  In short, 1 ml of overnight cultures 
were centrifuged and LB broth was decanted. Pelleted cells were re-suspended in 250μl 
buffer P1, and transferred to a new tube. 250μl buffer P2 was added and the tube was mixed 
thoroughly by inverting 4-6 times. 350μl buffer N3 was added and mixed immediately by 
inverting the tube 4-6 times. The mixture was centrifuged for 10min at 16,000xg. 
Supernatant was applied to the QIAprep spin column and centrifuged for 60sec, and the 
flow through was discarded. 0.5ml of wash buffer PB was added to filter, centrifuged for 
60sec, and the flow through was discarded. 0.75 ml buffer PE was added as a wash buffer, 
centrifuged for 60sec, and the flow through was discarded. The mixture was centrifuge for 
additional 1min to remove residual wash buffer.  To elute the DNA, the QIA prep column 
was placed in a clean 1.5 ml micro centrifuge tube, 50μl buffer EB was added to the center 
of each QIAprep spin column and centrifuged for 1 min. 
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2.6 Confirmation of Probe  
Restriction Digest using NotI  
NotI restriction enzyme (NEB) was used to cut the plasmid from SP6 and T7 
promoter regions and to isolate the gene product (800bp). This step was performed to 
confirm that the plasmid contains FAM171B gene. Restriction digest was performed by 
adding 5μl of 10X BSA buffer, 300μg mini-prep DNA template, 5μl 10X NEB 3.1 buffer, 
5μl NotI, 25μl of H2O, and the reaction digested overnight at 37°C. Appendix figure 3 
shows the confirmation of FAM171B after Restriction digest with NotI. 
After restriction digest using NotI, DNA samples were sent for sequencing (Genewiz) and 
sequencing data confirmed FAM171B DNA insert (Appendix figure 5 and 6).  
2.7 Linearization of FAM171B vector for Probe Generation  
Restriction Digest ApaI (50μl) reaction 
Restriction Digest at Sp6 promoter region of pGEM T-Easy vector was conducted 
using ApaI restriction enzyme. 5.6μg of DNA template, 2μl of ApaI (NEB), 5μl of Cut 
smart buffer (10x) and H2O (up to 50μl) were mixed in a 1.5 micro-centrifuge tube and 
incubated at 25°C for overnight. 
Restriction Digest using SalI 50μl reaction 
Restriction Digest at T7 promoter region of pGEM T-Easy vector was conducted 
using SalI restriction enzyme.  5.6μg of DNA template, 2μl of Sal1 (NEB), 5μl of Buffer 
3.1(10X) and H2O (up to 50μl) were mixed in a 1.5ml tube. The reaction mixture was 
digested overnight at 37°C. 
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Agarose gel electrophoresis was performed on a small portion (4μl) of restriction 
reactions to confirm plasmids were fully cut with SalI and ApaI restriction enzymes 
(Appendix Figure 7). The rest of the restriction reaction (46μl) was then purified using a 
QIAquick cleanup kit. In short, 230μl of PB was added to 46μl of restriction mix.  The 
reaction mixture was then placed to the QIA column and centrifuged for 60sec. After 
discarding the flow through, 750μl of buffer PE was added to the QIA quick column, 
centrifuged for 1 min, the flow through was discarded, and the column centrifuged for 
another 1min. To elute DNA, the QIAquick column was placed in a clean 2ml collection 
tube, 30μl buffer EB was added, and allowed to stand for 1min and eluate was collected by 
centrifugation. FAM171B purified digests were stored at -20ºC.  
2.8 In-vitro RNA Transcription Reaction 
RNA transcription was performed by adding DNA template (2µg), 5x transcription 
buffer (5.0 µl), 10mM DIG NTP mix (2.5 µl), RNAse inhibitor (1.0µl) and RNA 
polymerase SP6 or T7 (5.0 µl); water was added to adjust the final volume to 50µl. The 
solution containing DNA was then incubated at 37ºC for 2 hours.  2 µl of DNaseI (RNAse 
free) was added to the solution and incubated for 1 hour at 37ºC. A portion of the samples 
were then electrophoresed on 1% agarose gel in 1xTAE to confirm the presence of RNA 
probe, and that the DNA plasmid had been completely digested (Appendix Figure 8).  
SP6 and T7 promotor regions of the pGEM-T Easy vector and ApaI and SalI 
restriction enzymes were used to generate FAM171B experimental (Antisense) and 
FAM171B control (Sense) probes. Orientation of FAM171B was determined by DNA 
sequencing data (Appendix Figure 5 and 6). Thus, mRNA transcribed after vector cut at 
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SP6 promotor region was chosen as the antisense (Experimental) probe and mRNA 
transcribed after vector cut at T7 promotor region was chosen as the sense (Control) probe 
(Appendix Figure 6).  
Fragmenting RNA Probe: 
A heat block was set at 60ºC. 50 µl of 0.2M Na2CO3 and 50 µl of 0.2M NaHCO3 
(final pH=10.2) was mixed to make hydrolysis buffer. 100µl of the probe was then added 
to 100µl hydrolysis buffer and the mixture was incubated at 60ºC for 10min and placed on 
ice. 
To precipitate the RNA, 30 µl 2M Na acetate (pH=6.0) and 2.5 vol of 100% ethanol 
was added to each sample with each probe and incubated at -80ºC for an hour. The reaction 
was vortexed and centrifuged at 16000xg for 30 min at 4ºC and ethanol was decanted.  The 
precipitated RNA was then washed with 1 ml of 70% ethanol. Reaction was then 
centrifuged at 16000xg for 10 min at 4ºC and the pellet dried. The pellet was then re-
suspended in 50µl high molecular grade H2O. The concentration was measured using the 
Nano-drop and the probe re-suspended at 20ng/µl in Hybridization buffer.  
2.9 Mice Brains   
C57BL/6 mice colonies were reared (IRB: 15-02), and brain tissues were dissected 
from male mice of 4 different age groups: p7, p21, p42, and 6 months.  Brains were snap 
frozen in liquid nitrogen and stored at -80C until further processing. Frozen brains were 
sliced using a cryostat, and 12um sections were deposited onto charged glass slides (Fisher 
labs). Adult mouse brains were approximately 8mm wide. Since this study focused on the 
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left side of the brain, and sagittal brain sections were collected every 100 microns, each 
adult mouse brain produced ~40 sections. 
These thin sections of mouse tissue (that theoretically contain FAM171B) were 
then probed for indications of FAM171B mRNA expression. 
2.10 In-situ Hybridization for Mice Brain Tissues 
Day 1 
Pre-hybridization. 
Slides containing brain sections were fixed in 4% PFA / 1x DEPC-Tx PBS for 
10min, and washed twice in 1x DEPC-Tx PBS for 2 min. 
Tissue slices were acetylated in 0.1M TEA/0.25% Acetic Anhydride 10min. Next, 
tissues were permeablilized in 0.1% Triton X-100/PBS at RT for 10 min, and washed 3X 
with 1x DEPC-Tx PBS for 2 min using coplin jars.  Slides were transferred to a 
hybridization chamber and 500 µl of hybridization buffer (20ml of formamide, 8ml of 20X 
SSC, 0.8ml 50X Denhardts reagent, 8ml of 50% Dextran sulfate, 1.2ml DEPC water, 2ml 
of fish sperm DNA) was added to the slides and incubated at room temp 2 hr. Probe 
dilutions were made in hybridization buffer. To make 500ng/mL of probe, 125μl of 20ng/μl 
stock probe was mixed with 5ml of Hybridization buffer.  Probe was then heated at 80ºC 
5min to denature. Hybridization buffer already on the slides was removed and 250µl 
diluted probe was then added to slides, and cover-slipped. Slides were hybridized overnight 
at 57ºC after slides were placed in a tray containing paper towels moistened with 50% 
formamide/0.2X SSC.  
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Day 2 
Post hybridization 
Coverslips were removed by allowing them to slide off while in 1x SSC buffer. 
0.2xSSC was used to wash slides 4 times with 15mins intervals for 1 hr. at 68-72ºC in 
Coplin jars. Slides were then allowed to cool to room temperature, and washed with fresh 
RT 0.2xSSC for 5min.  
Antibody and alkaline phosphatase detection with BCIP/NBT 
Slides were washed in maleic acid buffer (MB) for 5min at room temperature. MB 
was removed and 30ml of 2% MBMB was added at RT for 1 hr. This blocking buffer was 
prepared by diluting 10% MBMB (Roche) 1x maleic acid buffer.  Slides were removed 
individually and placed on the humidified chamber and covered with 500μl anti-
Digoxygenin-AP antibody (Roche) diluted 1:2000 in 2% MBMB. Slides were incubated at 
room temperature for overnight. 
Day 3 
Post-antibody wash 
Slides were washed in MB for 30 min at room temp in Coplin jar. Then slides 
washed in color reaction buffer (100ml 0.5M Tris pH 9.5, 10ml 5M NaCl, 2.5ml of 1M 
MgCl2, 50µl Tween 20, and 387ml H2O) for 30min. NBT/BCIP color reaction solution was 
made by mixing 200ul NBT/BCIP stock and 10 ml of color reaction buffer. 500 µl of 
NBT/BCIP color reaction mixture was added to each slide.  Slides were incubated on a tray 
with dampened paper towels, covered in aluminum foil, and incubated 7 hours. 
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Day 4 
Mount slides 
Slides were washed 1xPBS for 5min at room temperature, and mounted using 
Aqua/Polymount (Polysciences). Once dry, slides were stored in at room temperature. 
 
2.11 Analyzing microscopic slides and densitometry 
After each in-situ, microscopic slides with mice brain sections were analyzed using 
a ZEISS Axiostar plus compound light microscope. Pictures of the experimental brain 
regions and control brain sections were taken using a progress C10 plus camera connected 
to the Axiostar plus compound light microscope.  
Densitometry was used to conduct the semi-quantitative analysis of the expression 
of FAM171B in different regions of the mouse brain. Two main brain regions 
(hippocampus and cerebellum) were selected based on the highest expression of 
FAM171B. ImageJ-NIH software was used to convert each image to 8-bit to get a grey 
scale picture. In each microscopic picture, the chosen brain region with the FAM171B 
expression was highlighted and selected using the “analyze” tool. Expression of FAM171B 
in each experimental brain region was measured and background stain (from nearby 
“white/non-stained” region in same image) was subtracted from original experimental 
measurement. Control brain images (stained with “control” probe) from corresponding 
regions were obtained and measured in an analogous fashion. The control brain 
measurements were then subtracted from the measurement obtained from the experimental 
brain region, and the results plotted in bar graph format. 
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2.12 Statistics 
Three mouse brains were collected for each age group (N=3), and each brain was 
micro-sectioned into 12 um sagittal brain sections.  From each brain, ~40 brain sections 
were obtained for the experimental probe, and 10 brain sections were obtained for the 
control probe. Thus, after three in-situ experiments, 120 brain sections per age group were 
analyzed both semi-quantitatively and qualitatively and compared to 30 control brain 
sections per each age group. Specifically, this analysis was performed by measuring 
FAM171B expression (in Ammon’s horn, Dentate gyrus, and cerebellum) in all 
experimental brain sections via densitometry (described above) ensuring that, the 
background staining of this region of the control samples was subtracted from the 
expression observed in experimental brain sections. Once the background was removed, 
and the expression level determined, the relative FAM171B expression of other age groups 
was normalized to P7. A univariate ANOVA test was then performed to determine whether 
or not the level of FAM171B expression was significantly different amongst the 4 age 
groups. 
2.13 Qualitative study 
A qualitative study was performed by observing the expression of FAM171B-
mRNA throughout the brain, specifically focusing on the Hippocampus, Cerebellum, 
Cortex, Amygdala, Thalamus, Caudate and Corpus callosum. For this part of the study, a 
compound microscope was utilized to examine the respective brain regions, and a 
qualitative score was ascribed for each region by visually comparing the experimental 
signal versus the control signal. Expression levels were assigned as follows: high signal 
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(+++), medium signal (++), low signal (+), and no signal (-). For this part of the study, 120 
experimental brain sections per age group were compared against 30 brain sections per age 
group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 21 
 
Chapter 3 
Results 
 
3.1 Confirmation of FAM171B in Mouse Cochlea  
  FAM171B DNA was sucessfully amplified using mouse cochlear DNA as the 
cDNA template. Electrophoresis and subsequent comparison to a 1 kb DNA ladder (Lane 
1) illustrate the presence of the desired 800bp fragment (Lanes 2 and 3). DNA sequence 
confirmed the PCR fragment was indeed FAM171B (Figure 6, Appendix). These results 
strongly suggest that FAM171B is indeed expressed, at the mRNA level, in mouse. 
 
 
 
 
 
 
 
 
 
Figure 1. Gel electrophoresis analysis confirming the presence of FAM171B in mouse 
cochlea. 1kb DNA ladder on the first lane. FAM171B DNA bands on the second and 
third lane. 
 
1KB MW FAM171B  FAM171B 
500bp 
1000bp 
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3.2 FAM171B mRNA expression in mouse brain  
In-situ hybridization strongly suggests that, FAM171B mRNA is expressed widely 
in mouse brain (Figure 2). In this figure, the presence of the purple color throughout the 
brain tissue confirms the expression of FAM171B at the mRNA level after performing an 
in-situ hybridization using the experimental probe. Even though, FAM171B is expressed 
throughout the majority of the brain, expression is more prominent (denoted by the darker 
purple color) in specific regions of the brain including the hippocampus, cortex, 
cerebellum, thalamus, caudate and amygdala (Figure 2).  
 
  
Figure 2. Sagittal brain section of a 21-day-old male mouse after performing in-situ 
hybridization with the experimental FAM171B mRNA probe. The image was obtained 
using a dissecting microscope on 10X magnification. HIPP correspond to the 
hippocampus, CTX stands for cortex, CRBL stands for cerebellum, THAL stands for 
thalamus, CN stands for caudate, and AMYG stands for amygdala. 
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3.3 Qualitative Analysis of FAM171B mRNA in mouse brain 
Qualitative analysis of the different regions of the mice brains confirmed a high 
level of FAM171B mRNA expression in all four age groups examined (Table 1). As 
anticipated, FAM171B was expressed throughout the mice brains of the experimental 
group as compared to those sections hybridized with the control probe, which revealed no 
expression. Although FAM171B mRNA expression was widespread in the brains of all 4 
age groups, much higher levels of expression were observed in the following regions: 
Dentate gyrus and Ammon’s horn of the hippocampus, Purkinje cell layer and granular 
layer of the cerebellum, motor and sensory cortices, amygdala, thalamus and the caudate. 
Interestingly, expression of FAM171B was absent in the the white matter of the brain, such 
as Corpus callosum. 
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Table 1.  Qualitative analysis of the expression of FAM171B mRNA in the different 
regions of the brains of mice belonging to different age groups after performing an in-situ 
hybridization. The +++ indicates the highest degree of expression, ++, moderate 
expression, +, low expression, and –, no expression. 
 
Brain Structures 
P7 
Experimental 
P21 
Experimental 
P42 
Experimental 
6M 
Experimental 
Ammons Horn +++ +++ +++ ++ 
Dentate Gyrus +++ +++ +++ ++ 
Caudate ++ ++ + ++ 
Cerebellum ++ ++ + + 
Thalamus ++ ++ + ++ 
Amygdala ++ ++ + ++ 
Corpus Callosum - - - - 
Motor Cortex ++ +++ ++ ++ 
Sensory Cortex ++ +++ ++ ++ 
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3.4 Detection of FAM171B mRNA Expression in Hippocampus  
Figure 3, illustrates FAM171B expression in the hippocampus of mice brains 
hybridized with the experimental (top panel) and control (bottom panel) probe. These data 
clearly indicate that FAM171B mRNA is strongly expressed in the hippocampus. All of 
the mice brains within the experimental group, regardless of age, exhibit a dark purple 
color following performance of the in-situ hybridization which suggests that FAM171B 
mRNA is highly expressed in this region. Control mice brains, on the other hand, (treated 
with a control FAM171B probe that contains the same exact mRNA sequence as the 
mRNA present in mice brain tissues), displays little to no purple color after performing the 
in-situ hybridization (Figure 3).  
 
Figure 3. FAM171B expression in the hippocampus of 7-day, 21-day, 42-day, and 6-
month-old mice. The image was observed using the 5X objective of a compound 
microscope.     
Experimental 
Control 
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Figure 4 illustrates prominent expression of FAM171B mRNA in the 
hippocampus of a sagittal brain section of a 21-day-old mouse model. This figure was 
captured after performing an in-situ hybridization of mice tissue using the experimental 
probe. The dark purple color indicates that FAM171B is highly expressed in both the 
Dentate Gyrus and the Ammon’s Horn regions of the hippocampus.  
  
 
Figure 4. FAM171B expression in the Dentate Gyrus and the Ammon’s Horn regions of 
the hippocampus of a 21-day-old mouse sagittal brain section hybridized with the 
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experimental probe. This image was observed using the 5X objective lens of a compound 
microscope.  
Semi-quantitative analysis also indicates that FAM171B mRNA is highly 
expressed in the Ammon’s Horn region of hippocampus of 7-day, 21-day, 42-day, and 6-
month old mice brains hybridized with the experimental probe (Figure 5). A univariate 
ANOVA test displayed a P value (P = 0.573) suggesting that the expression of FAM171B 
is not significantly different amongst the four age groups. 
 
 
 
 Figure 5. Semi-Quantitative analysis of FAM171B expression in Ammon’s Horn region 
of the hippocampus in mice brains of four different age groups.  
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Like Ammon’s Horn, FAM171B mRNA is also highly expressed in the Dentate 
Gyrus region of the hippocampus of experimental mice brains across all four age groups 
(Figure 6). A univariate ANOVA test displayed a P-value of 0.108, which suggests no 
significant difference in FAM171B expression amongst the different age groups. 
 
Figure 6. Semi-quantitative analysis of FAM171B expression in the Dentate Gyrus region 
of the hippocampus of mice brains belonging to different age groups.  
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3.5 Detection of FAM171B mRNA expression in the Cerebellum 
The dark purple staining in Figure 7 and 8 indicates that FAM171B mRNA is 
expressed in the cerebellum of an adult mouse brain. Upon closer inspection, it is clear that 
FAM171B mRNA expression is prominent in the Purkinje cell and granular cell layers, 
and the lowest in the molecular layer (Figure 8).  
 
 
Figure 7.  FAM171B mRNA expression in the cerebellum of a 6-month-old mouse brain 
treated with the experimental probe during in-situ hybridization. Images were obtained 
using the 5X (a) and 40 X (b) objectives of a compound microscope. 
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Figure 8. Qualitative analysis of FAM171B expression in cerebellum of mice brains in 
different age groups treated with experimental probe during in-situ hybridization compared 
to brains treated with control probe.  Pictures were taken at 5X objective under compound 
microscope. 
 
 
 
 
 
 
 
Experimental 
Control 
 31 
 
The one-way ANOVA test performed, based on the results of the densitometry 
(after normalization of the relative percent expression to P7), yielded a P value of P = 
0.440, suggesting that FAM171B expression in the cerebellum is not significantly different 
amongst the 4 different age groups (Figure 9). 
 
Figure 9.  Semi-Quantitative analysis of FAM171B expression on cerebellum in mice 
brains correspond to different age groups. 
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Chapter 4 
Discussion 
                FAM171B is an uncharacterized novel protein that contains polyglutamine 
residues within its amino acid sequence. Given the homology that is shares with proteins 
that result from mutated genes associated with polyglutamine diseases, FAM171B may 
also be linked to one or more neurodegenerative polyglutamine (polyQ) diseases. 
Unfortunately, the location or function of FAM171B is unknown, thus the current study 
was undertaken to localize the expression of FAM171B in mouse brains. Mice were 
selected as the model to study FAM171B because genomic sequence data shows that they  
are known carriers of the FAM171B protein. Moreover, the mouse FAM171B protein has 
88% homology with the human FAM171B protein and contains ~7 glutamine repeats 
(humans have ~ 16 repeats) (39). 
               The goal of the present study was to localize FAM171B mRNA in mice brains 
representing 4 different age groups (7-day (P7), 21-day (P21), 42-day (P42) and 6-month 
old (6M) mice) using in-situ hybridization. The data collected indicates that FAM171B 
mRNA is expressed widely throughout mice brains, regardless of age. However, upon 
closer examination of each brain section, it was observed that FAM171B expression is 
more prominent in some brain regions than others (Figure 2, Table 1). Densitometry data 
indicated there is no significant difference in expression of FAM171B mRNA among age 
groups, however since densitometry does not precisely measure the level of FAM171B-
mRNA expression, we consider this analysis as a semi quantitative analysis. 
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Qualitative analyses reveal that, of all the brain regions examined, the 
hippocampus seemed to exhibit the highest level of FAM171B mRNA expression (Table 
1). The hippocampus, which is a part of the limbic system and is located in the temporal 
lobe of the cerebral cortex, is an essential neuronal structure, responsible for playing a key 
role in consolidation of information from short term memory into long time memory. This 
structure is also responsible for storing and processing spatial memory that helps with 
navigation, with the dorsal portion being responsible for learning and forming memories 
(especially spatial navigation), and the ventral section primarily involved with anxiety 
associated behavior (26). Many polyglutamine neurodegenerative disorders (e.g., 
Huntington’s disease and Spinocerebellar Ataxia), result in impaired memory and 
dementia, which may be due to the impaired hippocampus functioning (38). Consequently, 
the expression of FAM171B mRNA in the hippocampus may suggest that this 
polyglutamine protein is linked to an underlying neurodegenerative disorder. 
             A high level of FAM171B mRNA expression was also observed in the cerebellum, 
the main structural feature of the hind-brain. Qualitative as well as semi-quantitative 
analyses confirm that FAM171B mRNA is highly expressed in this region of the brain 
(Figures 7, 8 and 9). The cerebellum is known to play a vital role in attention, language, 
emotional responses, addiction, pain, working memory, learning and pain (36).  Planning 
and execution of movements or motor control is another important function of the 
cerebellum in humans (27), although it should be noted that this structure does not initiate 
movements but is responsible for muscle coordination, precision and precise timing. 
Structurally, the cerebellum is divided in to three main layers: (1) the molecular, (2) 
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granular layer and (3) Purkinje cell layers. Of these, the granular layer is the deepest, 
consisting of densely packed granule cells (the smallest and most numerous neurons in the 
brain), Golgi cells also known as inhibitory interneurons, unipolar brush cells (excitatory 
glutamatergic interneurons), and Lugaro cells, sensory interneurons that performs 
inhibitory functions. The middle narrow layer consists of Purkinje cells, the most 
distinctive neurons in the brain that are typically recognized by the shape of their dendritic 
tree that branches profusely. Because Purkinje cells use GABA as neurotransmitter, they 
exert inhibitory effects on their target(s). Finally, the molecular layer, the outermost layer 
of the cerebellum, contains basket and stellate cells, both of which are inhibitory 
interneurons that forms GABAergic synapses with the dendrites of Purkinje cells. Of these 
3 layers, qualitative study indicates that the Purkinje cell and granular layers have the most 
prominent FAM171B mRNA expression in mice brains of all 4 age groups (Figure 9) 
although this expression is not significantly different among the different age groups. This 
finding suggests that FAM171B mRNA is present though out brain development of the 
mice.  
In many polyglutamine neurodegenerative disorders the cerebellum is the region of 
the brain that is impaired. According to Orr (28), Purkinje cells in the cerebellum are 
severely affected/lost in persons/mice afflicted with spinocerebellar ataxia type 1 (SCA 
type 1) because of the expanded number (~77) of glutamine residues in the SCA-1 gene 
product that produces the ataxin-1 protein and, consequently, ataxia. Studies by the above 
author (28) as well as Paulson et al., (12) suggest that overexpression of glutamine residues 
in the SCA3 gene in transgenic mice results rapid cell loss of Purkinje cells, leading to 
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cerebellar atrophy and ataxia. Moreover, SCA6 (spinocerebellar ataxia type 6), like SCA1, 
results in severe cell loss in the Purkinje cell layer of the cerebellum. It is very likely that 
Purkinje cell death in persons with SCA6 is caused by having an excess entry of calcium 
into the Purkinje cells because of the SCA 6 gene mutation (28). Finally, SCA type 17, 
Dentatorubral and pallidoluysian atrophy (DRPLA) and Huntington’s disease, other 
polyglutamine diseases caused by having an expanded number of CAG repeats within the 
mutated gene, results in severe alterations/degeneration in the cerebellum (16) (17) (29) 
(37). Given that FAM171B protein also contains polyglutamine repeats within its amino 
acid sequence and is highly expressed in the neuronal layers of the cerebellum (i.e., the 
Purkinje cell and granule cell layers) throughout development of the brain, this protein may 
have an underlying relationship with one or more polyglutamine disorders.  
Our data also shows that the caudate is another region of the brain that FAM171B 
mRNA is expressed in. Qualitative analysis of the results of the in-situ hybridization 
indicates that there is moderate expression of FAM171B mRNA in the caudate of mice 
models representing all 4 of the age groups (Table 1). This region of the brain is known to 
play a vital role as a feed-back processor where it uses the information from past experience 
to impact future actions and is also responsible for successful goal directed actions (30). In 
addition, the striatum, which is composed of both the caudate and the putamen, is 
responsible for multiple features of cognition including planning, motivation and decision 
making (30). According to Orr (28), the pathology of Huntington’s disease, which impairs 
most brain regions, results primarily from atrophy of the striatum, leading to a loss of 
GABA mediated neurons in this region. The same author also reports that neuronal loss, 
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specifically in striatum, hippocampus, thalamus and cortex, was observed in transgenic 
mice that expressed full length Huntington’s disease cDNA. However, the investigators of 
the abovementioned study concluded that the severity of Huntington’s disease depended 
upon the length of the polyglutamine tract, the level of the expression of the transgene in 
mice models and on the protein and the location of polyglutamine tract (28). Given these 
findings, the observation of FAM171B expression in the caudate in all age groups 
examined seems fascinating and may suggest a link to an underlying polyglutamine 
disorder since FAM171B has homology with genes associated with known polyglutamine 
disorders. 
The cerebral cortex, the region of the brain that covers the outer portion of the 
cerebrum, consists of many folded regions called gyri that increase the surface area of the 
brain and thus the amount of information that can be processed by the brain (32). This 
portion of the brain is responsible for many functions including motor movements, 
planning and organization, intelligence and personality determination, and the processing 
of language and sensory information (32). Damage to the cortex often results in ataxia, 
which is characterized by a lack of muscle coordination and balance. Ataxia is the most 
profound symptom of several types of spinocerebellar ataxias (SCA1, SCA3, SCA6, 
SCA17 and DRPLA) all of which are classified as polyglutamine neurodegenerative 
disorders. Although the cortex is affected in these above disorders, the pattern of 
degeneration and the relationship of cortical degeneration to the clinical symptoms can be 
difficult to assess due to the complex folding pattern of the cortex (28). Given the 
association of cortex damage and polyglutamine neurodegenerative disorders, it is not 
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surprising that in the present study, the cortex was found to express moderate levels of 
FAM171B mRNA among all age groups examined, with the most prominent expression 
observed in both the motor and sensory cortices. 
The thalamus, the brain’s relay center, is located below the corpus callosum of the 
brain and is considered a part of the forebrain. The thalamus is primarily responsible for 
conveying information from the sensory receptors to the appropriate region of the brain 
where the sensory information can be processed (28). As mentioned previously, neuronal 
loss in thalamus, among other areas of the brain, was observed in transgenic mice 
expressing full length Huntington’s disease cDNA (28). In addition, another study that 
mapped the MRI data of several Huntington’s disease patients revealed that both striatal 
and thalamic atrophy was prominent among this group (33). Therefore, the observation of 
moderate levels of FAM171B mRNA in the thalamus of mice models in all 4 age groups 
is intriguing.  
The amygdala, like the thalamus, exhibited moderate expression of FAM171B 
among all 4 age groups. This portion of the brain is located within the temporal lobes and 
is a part of a limbic system. The amygdala plays an important role in processing emotions 
such as anger, fear and pleasure (34) and also determines what memories are stored and 
where in the brain they are stored. Neurodevelopmental disorders such as Williams 
syndrome, Schizophrenia, anxiety and autism (34) are all known to affect the amygdala.  
PolyQ disorders, in contrast, do not routinely impair this part of the brain, although various 
levels of Amygdala neurodegeneration have been reported in some Huntington’s disease 
patients (35).  
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  The Corpus callosum, the large bands of white matter that do not have neuronal cell 
bodies, but connect the left and right hemispheres of the cerebrum, is involved in 
communication among the different parts of the brain. Qualitative analysis indicates that 
FAM171B mRNA is not expressed in this region of the brain in any of the 4 age groups 
examined. These data indicate that FAM171B may only be expressed in neuronal cell 
bodies (grey matter), but not in the white matter. Furthermore, additional research is needed 
to determine whether FAM171B is also expressed in glial cells such as astrocytes and 
microglia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 39 
 
Chapter 5 
Conclusion 
FAM171B is a novel protein that possesses a number of polyglutamine tracts (7 in 
mice vs. 16 in humans) but its function remains relatively unexplored. Sequence analysis 
of FAM171B, however, reveals that this protein shares some homology with other altered 
proteins involved in polyglutamine neurodegenerative disorders. Thus, the present study 
was preformed to examine expression levels of FAM171B mRNA in different regions of 
mice brains representing 4 different age groups (7-day-, 21-day-, 42-day- and 6-month-old 
mice).  Our findings indicate that although FAM171B mRNA is widely expressed in the 
brains of mice belonging to each age group, discernable differences in expression were 
apparent in the hippocampus, cerebellum, cortex, amygdala and thalamus. Our data also 
indicates that FAM171B mRNA is not expressed in the Corpus callosum, the large tracts 
of white matter between the left and right cerebral hemispheres, suggesting that FAM171B 
is most likely expressed only in neuronal cell bodies. In addition, the results of this study 
indicate that FAM171B mRNA expression is consistent among the 4 different age groups, 
implying that FAM171B is probably present in mice brains throughout their development. 
Given that FAM171B, like other polyQ proteins, contains a polyglutamine stretch and has 
high expression levels in the aforementioned brain regions, this protein may have an 
underlying role in one or more polyglutamine neurodegenerative disorders that have yet to 
be molecularly characterized. Future work includes examining FAM171B protein levels 
and expression patterns via immunohistochemistry, and investigating the intracellular 
expression of FAM171B using immunofluorescence techniques.  
 40 
 
References 
 
 
1. J. Madhusoodanan, Human Gene Set Shrinks Again   
Proteomic Data Suggest the Human Genome May Encode Fewer than 20,000 
genes.  The Scientist (2014). 
 
2. http://www.hprd.org/summary?hprd_id=13907&isoform_id=13907_1&isoform_n
ame.  
 
3. C. Landles, G. Bates P, Huntingtin and the Molecular Pathogenesis of 
Huntington's Disease.  EMBO Reports. 5, 958-963 (2004). 
 
4. R. Kirk, Genetics: Polyglutamine Repeats or Cancer? Nature Reviews. Clinical 
Oncology. 9, 308 (2012). 
 
5. H. Y. Zoghbi, H. T. Orr, Glutamine Repeats and Neurodegeneration. Annual 
Review Neuroscience. 23, 217-47 (2000). 
 
6. B. M. D. C. Godinho, M. Malhotra, C. M. O’Driscoll, J. F. Cryan, Delivering a 
Disease-Modifying Treatment for Huntington's Disease. Drug Discov. Today. 20, 
50-64 (2015). 
 
7. R. Brigit E, O. Harry T, Polyglutamine Neurodegenerative Diseases and 
Regulation of Transcription: Assembling the Puzzle. 6 (2006). 
 
8. B. T. Koshy, H. Y. Zoghbi, The CAG/Polyglutamine Tract Diseases: Gene 
Products and Molecular Pathogenesis. Brain Pathology. 7, 927-942 (1997). 
 
9. J. Shao, M. I. Diamond, Polyglutamine Diseases: Emerging Concepts in 
Pathogenesis and Therapy. Human Molecular Genetics. 16, R115-R123 (2007). 
 
10. H. Y. Zoghbi, H. T. Orr, Spinocerebellar Ataxia Type 1. Seminars in Cell 
Biology. 6, 29-35 (1995). 
 
11. J. Liu et al., Deranged Calcium Signaling and Neurodegeneration in 
Spinocerebellar Ataxia Type 2. The Journal of Neuroscience. 29, 9148-9162 
(2009). 
 
12. H. L. Paulson et al., Intranuclear Inclusions of Expanded Polyglutamine Protein 
in Spinocerebellar Ataxia Type 3. Neuron. 19, 333-344 (1997). 
 
 
 41 
 
13. K. Ishikawa et al., Abundant Expression and Cytoplasmic Aggregations of α1A 
Voltage-Dependent Calcium Channel Protein Associated with Neurodegeneration 
in Spinocerebellar Ataxia Type 6. Jour. 8, 1185-1193 (1999). 
 
14. M. Holmberg et al., Spinocerebellar Ataxia Type 7 (SCA7): A Neurodegenerative 
Disorder with Neuronal Intra-Nuclear Inclusions. Jour. 7, 913-918 (1998). 
 
15. E. O'Hearn, S. E. Holmes, R. L. Margolis, in Handbook of Clinical Neurology. 
103.535-547 
 
16. Y. Toyoshima, O. Onodera, M. Yamada, S. Tsuji, H. Hitoshi Takahashi, 
Spinocerebellar Ataxia Type 17. (2005). 
 
17. G. Schilling et al., Nuclear Accumulation of Truncated Atrophin-1 Fragments in a 
Transgenic Mouse Model of DRPLA. Neuron. 24, 275-286 (1999). 
 
18. A. Yamamoto, J. J. Lucas, R. Hen, Reversal of Neuropathology and Motor 
Dysfunction in a Conditional Model of Huntington's Disease. Cell. 101, 57-66 
(2000). 
 
19. A. J. Lechich MD, Huntington's Disease. Care Management Journals. 9, 63-4 
(2008). 
 
20. V. C. Wheeler et al., Length-Dependent Gametic CAG Repeat Instability in the 
Huntington's Disease Knock-in Mouse. Human Molecular Genetics. 8, 115-122 
(1999). 
 
21. D. L. Nelson, H. T. Orr, S. T. Warren, The Unstable Repeats--Three Evolving 
Faces of Neurological Disease. Neuron. 77, 825-843 (2013). 
 
22. N. Joyce et al., Mesenchymal Stem Cells for the Treatment of Neurodegenerative 
Disease. Regenerative Medicine. 5, 933-946 (2010). 
 
23. G. I. McFadden, Chapter 12 In-Situ Hybridization. Methods Cell Biol. 49, 165-
183 (1995). 
 
24. T. R. Moench, In-Situ Hybridization. Mol. Cell. Probes. 1, 195-205 (1987). 
 
25. C. P. Diethard Tautz, A Non-Radioactive In-Situ Hybridization Method for the 
Localization of Specific RNAs in Drosophila Embryos Reveals Translational 
Control of the Segmentation Gene Hunchback. Chromosoma. 98, 81-85 (1989). 
 
 42 
 
26. D. M. Bannerman et al., Regional Dissociations within the Hippocampus—
Memory and Anxiety. Neuroscience & Biobehavioral Reviews. 28, 273-283 
(2004). 
 
27. P. F. C. Gilbert, A Theory of Memory that Explains the Function and Structure of 
the Cerebellum. Brain Research. 70, 1-18 (1974). 
 
28. H. T. Orr, Beyond the Qs in the Polyglutamine Diseases. Cold Spring Harbor 
Laboratory Press. 15, 925-932 (2001). 
 
29. A. Hodges et al., Regional and Cellular Gene Expression Changes in Human 
Huntington's Disease. Brain Journal. 15, 965-977 (2006). 
 
30. J. A. Grahn, J. A. Parkinson, A. M. Owen, The Cognitive Functions of the 
Caudate Nucleus. Progress in Neurobiology. 86, 141-155 (2006). 
 
31. R. H. Myers et al., Decreased Neuronal and Increased Oligodendroglial Densities 
in Huntington's Disease Caudate Nucleus. Journal of Neuropathology & 
Experimental Neurology. 50, 729-742 (1991). 
 
32. R. Bailey, Anatomy of the Brain- Cerebral Cortex. Thoughtco. (2017). 
 
33. Kassubek J., Juengling FD., Ecker D., Landwehrmeyer GB., Thalamic Atrophy 
in Huntington's Disease Co-Varies with Cognitive Performance: A Morphometric 
MRI Analysis. Cerebellar Cortex. 15, 846-853 (2005). 
 
34. C. M. Schumann, M. D. Bauman, D. G. Amaral, Abnormal Structure or Function 
of the Amygdala is a Common Component of Neurodevelopmental Disorders. 
Neuropsychologia. 49, 745-759 (2011). 
 
35. M. P. Mattson, Pathogenesis of Neurodegenerative Disorders. Springer-
science+business Media, LLC. (2001). 
 
36. P. L. Strick, R. P. Dum, J. A. Fiez, Cerebellum and Nonmotor Functions. Annual 
Review of Neuroscience. 32, 413-434 (2009). 
 
37. C. Beste, C. Saft, O. Güntürkün, M. Falkenstein, Increased Cognitive Functioning 
in Symptomatic Huntington's Disease as Revealed by Behavioral and Event-
Related Potential Indices of Auditory Sensory Memory and Attention. The 
Journal of Neuroscience. 28 (2008). 
  
38. A. Michalik, C. Van Broeckhoven, Athogenesis of Polyglutamine Disorders:    
aggregation revisited. Jour. 12 (2003). 
 
 43 
 
39. https://www.ncbi.nlm.nih.gov/. National Center for Biotechnology Information     
Search Database. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 44 
 
Appendix 
 
 
7.1 pGEM-T Easy vector properties 
 
 
 
Figure 1: pGEM-T Easy vector map (www.promega.com) 
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7.2  Transformation of Vector to JM109 Bacteria 
 
Figure 2. Transformation of pGEM-T Easy vector to JM109 bacteria. Blue colonies 
indicate transformed vectors without the FAM171B insert. White colonies Indicate 
transformed vectors with FAM171B insert. 
 
Figure 2 contains JM109 bacterial colonies after transformed with pGEMT-Easy 
vector. These bacteria were grown in a media with ampicillin. Therefore, all these bacteria 
that grew in this specific media transformed the pGEM-T Easy vector because vector it-
self corresponded with ampicillin resistance. Since X-gal was also added to this media, it 
can recognize Lac-Z marker on the vector and change the color of the bacteria to blue color, 
if that marker was not interrupted by an insert in between. Therefore, bacterial colonies 
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that were colored in blue in this figure contains the pGEM-T Easy vector but not the 
FAM171B insert and white colonies contain the pGEM-T Easy vector with the FAM171B 
fragment.  
 
7.3 Confirmation of Restriction Digest with NotI 
  
 
Figure 3. Gel electrophoresis analysis confirming restriction digest of the vector with 
NotI enzyme. 1kb DNA ladder on the first lane. Uncut pGEM-T Easy vector with 
FAM171B on the second lane . pGEM-T Easy vector(3000bp) and FAM171B fragment 
(800bp) after restriction digest with NotI on the third lane. 
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Figure 3 indicates gel electrophoresis analysis of restriction digest of the pGEM-T 
Easy vector using NotI restriction enzyme. This procedure is only conducted to confirm 
to see if the vector contains the desired FAM171B fragment. NotI enzyme cuts at both 
SP6 and T7 promotor regions of the vector allowing to isolate the FAM171B fragment. 
Therefore, when pGEM-T Easy vector cut with NotI, we should be able to see two bands 
on the gel, one band corresponds to the size of the vector which is 3000bp and the other 
band corresponds to the size of the FAM171B, which is 800bp. Looking at two bands 
appeared on lane C of the figure 3 and by comparing to the size of the bands to the DNA 
ladder confirms that FAM171B is in the vector. This data was also confirmed by DNA 
sequencing. 
 
 
 
 
 
 
 
 
 
 
 
 
 48 
 
 
7.5 Primers used for Fam171B amplification 
 
Figure 4: Primers used in FAM171B amplification 
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7.4 DNA sequencing data for FAM171B 
 
Figure 5. DNA sequencing data for FAM171B on the SP6 Probe  
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Figure 6.  DNA Sequencing data for SP6 probe 
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7.5 Restriction Digest with ApaI and SalI 
  
Figure 7. Gel electrophoresis analysis of the Linearization of pGEM-T Easy vector using 
ApaI and SalI restriction enzymes. 1kb DNA ladder on the first lane. pGEM-T Easy 
vector cut with ApaI on the second lane . pGEM-T Easy vector cut with SalI on the third 
lane. 
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Figure 7 indicates the gel electrophoresis of restriction digest of pGEM-T Easy 
vector using ApaI and SalI.  ApaI restriction enzyme cuts at the sp6 promotor region of the 
vector and salI restriction enzyme cuts at the T7 promotor regions of the vector.  
Linearization is important because when we later conduct the in-vitro transcription of 
FAM171B, linearization helps to avoid transcription of mRNA in a circular manner. ApaI 
and SalI restriction enzymes helps to make control and experimental mRNA probes. Thus, 
we know the direction of Fam171B after the DNA sequencing, vector cut with ApaI 
identified as the experimental FAM171B contained plasmid and SalI, identified as the 
control FAM171B contained vector.  
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7.6 Confirmation of FAM171B mRNA after the transcription reaction 
Figure 8. Gel electrophoresis analysis of In-vitro transcription of FAM171B mRNA. 1kb 
DNA ladder (A).  Experimental probe sp6 promotor region cut with ApaI without DNase 
(B). Experimental probe sp6 promotor region cut with ApaI and DNase added (C). Control 
probe T7 promotor region cut with SalI without DNase (D). Control probe T7 promotor 
region cut with SalI and DNase added (E).  
 
               Figure 8 illustrates the in-vitro transcription of FAM171B using T7 and Sp6 
promotor regions. Experimental and control FAM171B mRNA probes were prepared using 
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ApaI and SalI restriction enzyme and by using SP6 and T7 promotor regions of the vectors. 
These experimental and control probes were designed based on the orientation of 
FAM171B DNA on mouse tissue from DNA sequencing data. Experimental FAM171B 
mRNA probe will have the complementary mRNA sequence to the mRNA present in 
mouse tissues whereas Control FAM171B mRNA probe will have the same sequence to 
the mRNA present in the mouse tissue. In lane B and D, DNA bands corresponds to the 
vector size present in both experimental and control probes due to not adding DNase. In 
lane C and E DNA bands corresponds to the size of vector are not present in both control 
and experimental probes in the gel due to addition of DNase. In lane C and E only the 
mRNA bands can be visualized. Since these mRNA was single stranded, mRNA tends to 
run in the gel in a distorted manner resulted creating various bands. FAM171B mRNA 
experimental and control mRNA probes were present in figure 5 between 1000bp and 
500bp band on the 1kb size standard. During this procedure, non-canonical DIG labeled 
bases and DNase were added in to the reaction mixture.  
 
 
 
 
  
